公开(公告)号：WO2021011853A2

公开(公告)日：2021-01-21

申请号：PCT/US2020/042475

申请日：2020-07-17

Applicant: YALE UNIVERSITY

Inventor： FLAVELL, Richard ,  HALENE, Stephanie ,  SONG, Yuanbin

IPC: C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/79 ,  C12N15/85 ,  C07K14/53 ,  A01K67/027

Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.

公开(公告)号：WO2019199808A1

公开(公告)日：2019-10-17

申请号：PCT/US2019/026562

申请日：2019-04-09

Applicant: THE WISTAR INSTITUTE

Inventor： SOMASUNDARAM, Rajasekharan ,  MUTHUMANI, Kar ,  WEINER, David

IPC: C07K14/505 ,  C07K14/52 ,  C07K14/53 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71

Abstract: The present invention relates to recombinant optimized polynucleotide encoding a cytokine or cytokine receptor and to methods of making a recombinant optimized polynucleotide encoding a cytokine or cytokine receptor.

公开(公告)号：WO2004022593A8

公开(公告)日：2007-05-18

申请号：PCT/IB0304347

申请日：2003-09-08

Applicant: NAUTILUS BIOTECH ,  GANTIER RENE ,  GUYON THIERRY ,  VEGA MANUEL ,  DRITTANTI LILA

Inventor： GANTIER RENE ,  GUYON THIERRY ,  VEGA MANUEL ,  DRITTANTI LILA

IPC: A61K38/00 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/53 ,  C07K14/535 ,  C07K14/54 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C12N15/19 ,  C12N15/20 ,  C12N15/24

CPC classification number: C07K14/475 ,  A61K38/00 ,  C07K14/505 ,  C07K14/52 ,  C07K14/53 ,  C07K14/535 ,  C07K14/54 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61

Abstract: Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.

Abstract translation: 提供了肽和蛋白质，特别是在复杂生物学环境中起作用的细胞因子的高通量定向进化的方法和系统。 还提供了用于产生蛋白质变体和所得变体的合理方法。

公开(公告)号：WO2004024777A8

公开(公告)日：2005-03-24

申请号：PCT/EP0308859

申请日：2003-08-08

Applicant: FRESENIUS KABI DE GMBH ,  ZANDER NORBERT ,  CONRADT HARALD ,  EICHNER WOLFRAM

Inventor： ZANDER NORBERT ,  CONRADT HARALD ,  EICHNER WOLFRAM

IPC: A61K8/73 ,  A61K9/00 ,  A61K9/14 ,  A61K38/00 ,  A61K38/18 ,  A61K47/48 ,  C07K14/505 ,  C07K14/53 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K17/06 ,  C07K17/10 ,  C08B31/00 ,  C08B31/08 ,  C08B31/12 ,  C08B33/04 ,  C08B35/04 ,  C12N15/12

CPC classification number: C08B31/12 ,  A61K9/0021 ,  A61K38/00 ,  A61K47/61 ,  C07K14/505 ,  C07K14/53 ,  C07K14/5412 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K17/10 ,  C08B31/00 ,  C08B31/006 ,  C08B31/08 ,  C08B31/185 ,  C08H1/00

Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R'NH-R'' (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R' or R'' or R' and R'' comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.

Abstract translation: 本发明涉及一种生产羟烷基淀粉衍生物的方法，包括使式（I）的羟烷基淀粉在其还原末端反应，其在所述反应之前未被氧化，与式（II）化合物R'NH-R“ （II）其中R1-R2和R3独立地是氢或直链或支链羟烷基，并且其中R'或R“或R'和R”包含至少一个能够至少与其反应的官能团X （I）和（II）反应之前或之后的另一种化合物，以及可通过所述方法获得的羟烷基淀粉衍生物，以及包含所述羟烷基淀粉衍生物的药物组合物。

公开(公告)号：WO0207676A3

公开(公告)日：2002-05-10

申请号：PCT/US0123046

申请日：2001-07-20

Applicant: GLAXO GROUP LTD ,  CWIRLA STEVEN E ,  BALU PALANI ,  DUFFIN DAVID J ,  PIPLANI SUNILA ,  MCEOWEN MERRILL BARBARA ,  SCHATZ PETER J

Inventor： CWIRLA STEVEN E ,  BALU PALANI ,  DUFFIN DAVID J ,  PIPLANI SUNILA ,  MCEOWEN-MERRILL BARBARA ,  SCHATZ PETER J

IPC: A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/53 ,  C07K14/535 ,  C07K7/00

CPC classification number: C07K14/53 ,  A61K38/00 ,  C07K14/535

Abstract: Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.

Abstract translation: 提供结合G-CSFR的新型化合物。 新化合物具有长度约6至40个氨基酸的肽链，其结合G-CSFR。 该化合物可用作亲和筛选的探针。 此外，化合物已经证明了对于G-CSFR的激动剂或拮抗剂活性，因此可用于治疗疾病，包括患有低白细胞滴度的患者。 也提供药物组合物和使用方法。

公开(公告)号：WO01053327A2

公开(公告)日：2001-07-26

申请号：PCT/US2001/002235

申请日：2001-01-24

IPC: C07K1/00 ,  C07K1/04 ,  C07K7/08 ,  C07K14/53 ,  G06F19/16 ,  G06F19/22

CPC classification number: G06F19/22 ,  C07K1/00 ,  C07K1/047 ,  C07K7/08 ,  C07K7/083 ,  C07K14/53 ,  G06F19/16

公开(公告)号：WO99009052A1

公开(公告)日：1999-02-25

申请号：PCT/US1998/016217

申请日：1998-08-05

IPC: A61K38/00 ,  A61K47/48 ,  A61P3/04 ,  A61P7/00 ,  A61P43/00 ,  C07K1/107 ,  C07K14/53 ,  C07K14/535 ,  C07K14/575 ,  A61K38/17

CPC classification number: C07K1/1077 ,  A61K38/00 ,  A61K47/54 ,  A61K47/547 ,  C07K14/53 ,  C07K14/535 ,  C07K14/5759

Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More spcecifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.

Abstract translation: 本发明广泛涉及生物活性蛋白质或其类似物的化学修饰。 更具体地，本发明描述了用于各种蛋白质的位点特异性化学修饰的新方法，以及具有改善的生物相容性和生物活性的所得组合物。

公开(公告)号：WO2020069515A1

公开(公告)日：2020-04-02

申请号：PCT/US2019/053852

申请日：2019-09-30

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER

Inventor： STUDER, Lorenz ,  GUTTIKONDA, Sudha, Ragavalli

IPC: C07K14/53 ,  C12N5/00

Abstract: The present disclosure relates to methods for generating microglial cells derived from stem cells (e.g, human stem cells), microglial cells obtained from such methods and compositions comprising thereof, and uses of said microglial cells for disease modeling and for treating microglia related disorders.

公开(公告)号：WO2015164107A1

公开(公告)日：2015-10-29

申请号：PCT/US2015/025514

申请日：2015-04-13

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： GALIPEAU, Jacques ,  PENNATI, Andrea

IPC: C07K19/00 ,  C07K14/53 ,  C07K14/535 ,  C07K14/54 ,  C12N15/62 ,  A61K38/19 ,  A61K38/20 ,  A61P37/06

CPC classification number: C07K14/535 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0008 ,  A61K45/06 ,  A61K2039/515 ,  C07K14/5406 ,  C07K14/5425 ,  C07K14/5443 ,  C07K14/55 ,  C07K2319/00 ,  A61K2300/00

Abstract: This disclosure relates to recombinant proteins comprising a GM-CSF sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises N-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer.

Abstract translation: 本公开涉及包含GM-CSF序列和白介素序列的重组蛋白质以及与其相关的核酸。 在某些实施方案中，本公开涉及重组蛋白质，其包含作为治疗或预防自身免疫疾病如多发性硬化和癌症的生产技术和用途的结果的N末端序列。

公开(公告)号：WO2012057529A2

公开(公告)日：2012-05-03

申请号：PCT/KR2011008046

申请日：2011-10-26

Applicant: HANMI HOLDINGS CO LTD ,  CHOI SUNG CHUL ,  KIM JIN KI ,  OH YOUNG HAK ,  LEE JONG SOO

Inventor： CHOI SUNG CHUL ,  KIM JIN KI ,  OH YOUNG HAK ,  LEE JONG SOO

IPC: C07K14/53 ,  C07K1/16 ,  C12N15/27 ,  C12N15/70

CPC classification number: C07K1/36 ,  C07K14/535

Abstract: The present invention provides a method for purifying a large amount of human granulocyte-colony stimulating factors (hG-CSFs) from a recombinant E. coli with high yield and purity. According to the method of the present invention, human granulocyte-colony stimulating factor, identical to the native form expressed in the human body, can be easily purified with high yield and purity without an additional activation process. In particular, according to the purification method of the present invention, hG-CSF variants expressed in E. coli are efficiently removed to obtain physiologically active hG-CSFs with high purity.

Abstract translation: 本发明提供了从重组大肠杆菌以高产率和高纯度纯化大量人粒细胞集落刺激因子（hG-CSF）的方法。 根据本发明的方法，与人体中表达的天然形式相同的人粒细胞集落刺激因子可以容易地以高收率和纯度纯化而无需额外的活化过程。 具体而言，根据本发明的纯化方法，在大肠杆菌中表达的hG-CSF变体被有效地去除以获得高纯度的生理活性hG-CSF。